Atlas Trials

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Clinical trial NCT01597908 · COMPLETED

Trial details

NCT number
NCT01597908
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Melanoma
Start date
2012-06-04
Primary completion
2014-04-17
Enrollment
704

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.